(MM) (NPSP) Cotización

Agreed, it's disappointing to only get a few bucks over the Friday close, especially without the natpara approval yet in hand. Wonder if that is approved next week what will happen here...

But I'll take it no doubt!

Disappointed in that buyout price

Going to be crazy day in here tomorrow

Buyout by Shire announced...$46 per share

NPSP M

***The FDA is expected to decide on the drug on Jan. 24, 2015.

If approved, NPS plans to launch Natpara in the second quarter of 2015.

Although NPS is high on Shire's list of potential deals, other targets are also being considered, Bloomberg said.

(Reuters) - Dublin-based Shire Plc (SHP.L), whose proposed sale to AbbVie Inc (ABBV.N) fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc (NPSP.O), Bloomberg reported, citing people familiar with the matter.

NPS's shares rose as much as 23 percent to $37.50 (23.9 pounds) on the Nasdaq. Shire's shares were up 1.3 percent on the London Stock Exchange.

The timing of a possible bid would depend on whether the U.S. Food and Drug Administration approves NPS's hormone replacement therapy Natpara, two of the people told Bloomberg.

Natpara is designed to treat low levels of the parathyroid hormone (PTH), which causes hypoparathyroidism.

The FDA is expected to decide on the drug on Jan. 24, 2015.

If approved, NPS plans to launch Natpara in the second quarter of 2015.

Although NPS is high on Shire's list of potential deals, other targets are also being considered, Bloomberg said.


Shire and NPS were not immediately available for comment.


AbbVie pulled the plug on its plan to buy Shire, blaming new U.S. tax rules aimed at curtailing tax inversion deals.


(Reporting by Devika Krishna Kumar in Bengaluru; Editing by Siddharth Cavale)

NPS Pharmaceuticals Inc.'s (NPS) shares hit stratosphere; up over 18%, after Bloomberg reported that Shire PLC might be working on an offer for the Company, after its bid for AbbVie Inc. collapsed. Read more about the potential bid and the stock's reaction to it in our research report.

$NPSP DD Notes ~ http://www.ddnotesmaker.com/NPSP

bullish
long term buy and hold

$NPSP recent news/filings

## source: finance.yahoo.com

Wed, 17 Dec 2014 17:10:32 GMT ~ Shire considering bid for NPS Pharmaceuticals - Bloomberg


read full: http://sg.finance.yahoo.com/news/shire-considering-bid-nps-pharmaceuticals-171032573.html
*********************************************************

Wed, 17 Dec 2014 17:06:10 GMT ~ Shire considering bid for NPS Pharmaceuticals - Bloomberg

[Reuters - UK Focus] - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar ...

read full: http://uk.finance.yahoo.com/news/shire-considering-bid-nps-pharmaceuticals-170610879.html
*********************************************************

Wed, 17 Dec 2014 17:06:10 GMT ~ Shire considering bid for NPS Pharmaceuticals - Bloomberg

[Reuters] - Dublin-based Shire Plc, whose proposed sale to AbbVie Inc fell apart in October, is considering an offer for U.S-based drug developer NPS Pharmaceuticals Inc, Bloomberg reported, citing people familiar ...

read full: http://finance.yahoo.com/news/shire-considering-bid-nps-pharmaceuticals-170610029.html
*********************************************************

Wed, 17 Dec 2014 16:44:18 GMT ~ BUZZ-NPS Pharma Inc: Shire considering bid - Bloomberg

[Reuters - UK Focus] - ** Shire Plc considering bid for NPS Pharmaceuticals Inc, Bloomberg reports ** U.S. biopharma company NPS's shares up 21.3 pct at $36.95 in heavy trading ** Ireland-based Shire's shares up 1.9 pct at $212.64 ...

read full: http://uk.finance.yahoo.com/news/buzz-nps-pharma-inc-shire-164418460.html
*********************************************************

Wed, 17 Dec 2014 16:01:43 GMT ~ Shire Said to Weigh Offer for NPS as It Revisits Deals


read full: http://www.bloomberg.com/news/2014-12-17/shire-said-to-weigh-offer-for-nps-as-it-revisits-deals.html?cmpid=yhoo
*********************************************************


$NPSP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NPSP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NPSP/company-info
Ticker: $NPSP
OTC Market Place: Not Available
CIK code: 0000890465
Company name: NPS Pharmaceuticals, Inc.
Incorporated In: DE, USA


$NPSP share structure

## source: otcmarkets.com

Market Value: $3,856,913,459 a/o Dec 17, 2014
Shares Outstanding: 106,839,708 a/o Nov 03, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$NPSP extra dd links

Company name: NPS Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NPSP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NPSP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NPSP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/news - http://finance.yahoo.com/q/h?s=NPSP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NPSP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NPSP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NPSP
DTCC (dtcc.com): http://search2.dtcc.com/?q=NPS+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NPS+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NPS+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NPSP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000890465&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NPSP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NPSP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NPSP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NPSP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NPSP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NPSP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NPSP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NPSP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NPSP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NPSP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NPSP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NPSP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NPSP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NPSP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NPSP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NPSP



$NPSP DD Notes ~ http://www.ddnotesmaker.com/NPSP

SCAN FROM SC

NPSP D

What's that?

THANKS
Just started to watch, since it showed up on plus 10 % scan

No idea but I'm not complaining. Still prime candidate for a buyout though. We'll see what's behind the buying soon enough I suppose.

why the big gain today ?

My biggest gainer today. Thank goodness!

A few insiders selling shares... In guessing they aren't in any takeover negotiations or else they wouldn't be selling... Guess the next catalyst will have to wait until Jan Natpara approval

$NPSP DD Notes ~ http://www.ddnotesmaker.com/NPSP

bullish
nice breakout over long term resistance
moving averages now acting as support
long term bull flag breakout in progress

$NPSP recent news/filings

## source: finance.yahoo.com

Tue, 11 Nov 2014 21:10:00 GMT ~ NPS Pharma to Present at Jefferies Global Healthcare Conference

[Business Wire] - NPS Pharmaceuticals, Inc. is scheduled to present at the Jefferies 2014 Global Healthcare Conference in London on Thursday, November 20, 2014 at 8:00 a.m. WET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentations have concluded.

read full: http://finance.yahoo.com/news/nps-pharma-present-jefferies-global-211000250.html
*********************************************************

Tue, 11 Nov 2014 15:50:02 GMT ~ NPS Pharmaceuticals Incurs Wider Q3 Loss, Revenues Miss


read full: http://finance.yahoo.com/news/nps-pharmaceuticals-incurs-wider-q3-155002778.html
*********************************************************

Mon, 10 Nov 2014 21:39:57 GMT ~ NPS reports 3Q loss


read full: http://sg.finance.yahoo.com/news/nps-reports-3q-loss-213957014--finance.html
*********************************************************

Mon, 10 Nov 2014 21:39:57 GMT ~ NPS reports 3Q loss


read full: http://finance.yahoo.com/news/nps-reports-3q-loss-213957016.html
*********************************************************

Mon, 10 Nov 2014 21:06:44 GMT ~ NPS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E


read full: http://biz.yahoo.com/e/141110/npsp8-k.html
*********************************************************


$NPSP charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$NPSP company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/NPSP/company-info
Ticker: $NPSP
OTC Market Place: Not Available
CIK code: 0000890465
Company name: NPS Pharmaceuticals, Inc.
Incorporated In: DE, USA


$NPSP share structure

## source: otcmarkets.com

Market Value: $3,090,283,674 a/o Nov 17, 2014
Shares Outstanding: 106,561,506 a/o Jul 30, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$NPSP extra dd links

Company name: NPS Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=NPSP+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=NPSP+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=NPSP+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/news - http://finance.yahoo.com/q/h?s=NPSP+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/NPSP/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=NPSP+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/NPSP
DTCC (dtcc.com): http://search2.dtcc.com/?q=NPS+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=NPS+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=NPS+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/NPSP
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000890465&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=NPSP&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=NPSP
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=NPSP+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=NPSP+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=NPSP
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=NPSP
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=NPSP+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/NPSP/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=NPSP+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/NPSP.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=NPSP
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/NPSP/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/NPSP/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/NPSP
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/NPSP
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/NPSP:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=NPSP
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=NPSP



$NPSP DD Notes ~ http://www.ddnotesmaker.com/NPSP

Still buyout candidate as far as I know..

$NPSP Brean Capital Reiterates Buy On NPS Pharmaceuticals Following 3Q14 Results http://www.smarteranalyst.com/2014/11/11/brean-capital-reiterates-buy-on-nps-pharmaceuticals-following-3q14-results/

Not sure it'd be a surprise! Natpara is bound to be approved, but NPSP always rises in anticipation of good news like this. Strong buy for sure.

Abvie's dropout means Shire may look at NPSP again. This could significantly boost upside potential. Both speculation about Shire and the impending Natpara approval mean this stock is trading at a DISCOUNT. :)))

When I saw the news about Abvee I had the same thoughts. Combine that possibility with the natpara approval coming at the EOM and we're primed for some good upside. Only question will be the overall markets weighing it down.

The FT and Reuters both reported that Shire had lined up financing for NPS in May 2014...
And now AbbVie is likely to walk away from Shire - paying $1.6bn in the process...
now lets think..."what shall we buy??"

NPSP about to surge to 35ish

It always does this before news, regardless of the outcome. Natpara approval coming up. Might be wise to ride this one up.

PDUFA for NATPARA 10/24/14.
AdCom vote was 8-5 for approval.
Maybe 10% upside here from $23; market just sucks right now.

$NPSP Janney Reiterates Buy On NPS Pharmaceuticals As FDA Panel Backs Natpara Approval http://www.smarteranalyst.com/2014/09/15/janney-reiterates-buy-on-nps-pharmaceuticals-as-fda-panel-backs-natpara-approval/

Plain sell on the news, as 8-5 vote in favor shows clear majority ?

Got an approval and down over $1 after hours? What am I missing?

Stock halted thru the committee vote. Should be interesting come 5pm.

NPSP and OREX both getting a scare here. Both have odds in their favor. No guts, no glory.

A surprise would be nice...

To the upside anyway. The volatility of this stock is getting old. Another 4% drop today with no news I could find. What is driving the price of this stock?

Go NPSP

We Think NPSP Could Surprise To The Upside, Says Wedbush http://www.smarteranalyst.com/2014/08/04/we-think-npsp-could-surprise-to-the-upside-says-wedbush/

Needs a positive vote. Too easy. $40 stock IMO

Where is this going?

In the past 30 days, this has dropped from around $34.00 to it's current price of around $27.00 a share. I guess the buyout rumors have totally worn out and we are back to the roller coaster that is NPSP. Seems strange that even when good news hits, there is a negative effect on the price. This is a tough one to figure out...

Go NPSP

$7 million buy at the close. Someone is accumulating...

1M shares AH

With all the recent news about a takeover Bid for Shire what do you think the impact to NPSP will be?
I'm wondering if Shire truly doesn't want to be acquired they'll up their NPSP offer and hopes that will be a poison pill for anyone trying to take then over.

Thoughts?

Would be nice to hear something.

This is from Bloomberg all the way back on June 5th...


With drugmakers pursuing deals like never before, Shire Plc (SHP)’s best defense against becoming a target may be to go on the hunt itself.

Reports last week that Shire is weighing a bid for NPS Pharmaceuticals Inc. (NPSP) have pushed that company’s shares up 20 percent. While NPS said it hasn’t held talks with Shire about a deal, Piper Jaffray Cos. said Shire needs to make purchases if it wants to keep from being gobbled up amid the record $139 billion in pharmaceutical deals that were announced so far this quarter. Dublin-based Shire has been speculated as a takeover candidate because of the $35 billion company’s Irish tax base and focus on fast-growing rare-disease treatments.

“If they want to stay independent, then going on a bit of a shopping spree makes it harder for another entity to go after them,” David Amsellem, a New York-based analyst at Piper Jaffray said in a phone interview. “They will be approached. They probably have been approached.”

NPS, a $3.5 billion maker of medicines for short-bowel syndrome and hypoparathyroidism, would be a logical acquisition candidate for Shire because it would bolster the company’s portfolio of rare-disease drugs, according to Wedbush Inc. Other possible targets for Shire, which has increased its dealmaking the last two years, may include muscular dystrophy drug developers Prosensa Holding NV (RNA) and Sarepta Therapeutics Inc. (SRPT), said Cenkos Securities Plc.

Jessica Mann, a representative for Shire, said the company doesn’t comment on M&A speculation.

Well, Now what???

So Bob what's the word, does it look like a buyout to you?

Well this is rather confusing.

NPSP files an 8-K to dispel rumors of a potential buyout. What are the lawyers going to do now?


- - - - - - - - - - - - - -

Item 7.01 Regulation FD Disclosure.

Although it is generally NPS Pharmaceuticals, Inc.’s (“NPS”) policy not to comment on media speculation and market rumors, in light of the erroneous press reports that Shire Plc (“Shire”) has had communications with NPS concerning a purported offer by Shire to acquire NPS, NPS confirmed that to date NPS has not had any communication with Shire or any representative of Shire concerning the acquisition of NPS by Shire. NPS intends to continue its policy of not commenting on media speculation and market rumors and undertakes no obligation to update the information contained in this Report.



In accordance with General Instruction B.2 of Form 8-K, the information contained in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and such information shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act unless specifically stated.

- - - - - - - - - - - - - -

The next few days should be interesting.

Here Come the Lawyers...

No offense to any members of the legal profession, but when this stuff happens, you can pretty much bank on this being a done deal.


SHAREHOLDER ALERT: Pomerantz LLP Investigates Claims That the Merger May Not Be in the Best Interest of Investors of NPS Pharmaceuticals, Inc. - NPSP
12:34p ET June 2, 2014 (PR NewsWire) Print

Pomerantz LLP is investigating claims on behalf of investors of NPS Pharmaceuticals, Inc. ("NPS Pharmaceuticals" or the "Company") (Nasdaq: NPSP) (ISIN: US62936P1030) (CUSIP: 62936P103) concerning the proposed acquisition of NPS Pharmaceuticals by Shire Plc.

NPS Pharmaceuticals shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The investigation concerns whether the NPS Pharmaceuticals directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, each share of NPS Pharmaceuticals will be exchanged for $40 in cash. However, the Price to Revenue and Book Value multiples are below comparable transactions' averages, and at least one Analyst set target price of $44 per NPS Pharmaceuticals share.

Pomerantz LLP, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz LLP pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz LLP continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.

CONTACT: Robert Willoughby Pomerantz LLP 212-661-1100 ext. 237 rswilloughby@pomlaw.com

SOURCE Pomerantz LLP

Buyout Offer Is Much Better Than $40/Share

It looks like the offer will be around $50/share. See story below:

(Reuters) - London-listed drugmaker Shire Plc has secured a $5 billion credit facility for a takeover offer for New-Jersey-based NPS Pharmaceuticals, The Times of London reported on Sunday.

The newspaper said Shire has lined the credit facility for NPS, which is being advised by Goldman Sachs, from banks led by Citigroup. (link.reuters.com/kuk79v)

Insiders told The Times that an initial approach to NPS by Shire has been rebuffed. However, a former London hospital doctor with ties to both companies is acting as a go-between, the daily said.

The Times reported that Colin Broom, who is on the board of NPS and the chief scientific officer of U.S. company ViroPharma that was taken over by Shire last year, would be a key figure in the takeover talks.

The Financial Times blog, Alphaville, was the first to report on Shire considering a bid for NPS Pharma on Friday.

Shire could not be contacted for comment outside of normal business hours.

http://www.reuters.com/article/2014/06/01/us-shire-m-a-nps-idUSKBN0EC1YO20140601

Possible Buyout??

Shares of NPS Pharmaceuticals, a biopharmaceutical company focused on developing therapies to treat rare diseases, skyrocketed as much as 26% after rumors surfaced that it could be the target of a buyout.

According to a report from FT Alphaville, which cited familiar sources, Shire (NASDAQ: SHPG) has held internal talks and has been working with its advisors to possible arrange an all-cash offer for NPS Pharmaceuticals of around $40 per share. If Financial Times' blog is accurate, it would represent a valuation in excess of $4 billion for NPS and place a premium of roughly 50% on the company compared to yesterday's closing price. As of this writing, no comment has been issued by either Shire or NPS concerning the matter

Well, the stock sure jumped today...

Down another 4% when the Market is UP

The market had a great day with gains all around. Not NPSP. Any reason for the pullback?

Tanking again.

Can anyone give me a hint why this stock is a roller coaster? I am having trouble understanding the huge moves on what appears to be no news. Perhaps I am not looking in the right places?

NPSP was one of Zack's 10 best for this year so I did a little research and bought a small position at the beginning of the year. I am starting to wonder if I will ever see green again.

Very great stock here with Gattex and Natpara...I use this stock as my checking account...

Should see 30 by mid next week with a healthy pull back before earnings.

The earnings are coming out on May 8th, I believe.